CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Recruiting now

Conditions studied: Breast Cancer

In brief

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Key facts

Study ID

NCT06927648

Run by

AstraZeneca

People needed

130

Starts

2025-10-15

Expected to finish

2029-12-30

Last updated by the study team

2026-07-07

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients eligible for and treated with the study drug according to the approved label in South Korea
• Patients who provide signed and dated written informed consent, either personally or through a legally acceptable representative.

You may not qualify if…

• Participation in any interventional trial during the treatment of the study drug
• Other off-label indications according to the approved label in South Korea

Where it is running

• Research Site — Uijeongbu-si, South Korea (enrolling)
• Research Site — Incheon, South Korea (enrolling)
• Research Site — Seoul, South Korea (enrolling)
• Research Site — Seoul, South Korea (enrolling)
• Research Site — Seoul, South Korea (enrolling)
• Research Site — Suwon, South Korea (enrolling)
• Research Site — Busan, South Korea (enrolling)
• Research Site — Daejeon, South Korea (enrolling)
• Research Site — Goyang-si, South Korea (enrolling)
• Research Site — Goyang-si, South Korea (enrolling)
• Research Site — Guri-si, South Korea (enrolling)
• Research Site — Incheon, South Korea (enrolling)
• Research Site — Busan, South Korea
• Research Site — Busan, South Korea
• Research Site — Daejeon, South Korea
• Research Site — Seongnam-si, South Korea
• Research Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.